Program: Oral and Poster Abstracts
Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster I
METHODS: We conducted individual interviews with patients with AML (median age=48, 37% male) in Japan and the USA following a semi-structured interview guide, containing both open- and closed- ended questions. These questions aimed to understand the patient’s experience both spontaneously and with specific probing. Patients were asked to describe their individual experience of living with AML including signs, symptoms, impacts, and the experience during treatment of the disease.
RESULTS: Forty-one patients were interviewed in the two regions: 23 in US, and 18 in Japan. The sign, symptom, and impact ‘concepts’ identified were very similar across regions. Forty-nine symptoms were mentioned by US patients; 32 by Japanese patients. The signs/symptoms reported most frequently and as most bothersome included: fatigue, bruising, weakness, dizziness, shortness of breath, and bleeding (Table 1). Twenty-three unique impacts of signs/symptoms were mentioned in the US and 20 in Japan. The most frequent and bothersome impacts reported included: decreased ability to maintain social/familial roles, anxiety, decreased ability to function, depression, fear, remission uncertainty, appetite loss, and low sex drive (Table 1). These concepts were corroborated by two additional sources: interviews with clinicians and published literature.
DISCUSSION: The priority concepts expressed by patients were relevant and important to all four AML patient groups in both regions. This data provides valuable insight into patients’ experiences with AML and helps to select the appropriate patient-reported outcomes for clinical trials.
Table 1. AML Symptom and Impact Frequencies
|
US Frequency (N=23), n (%) |
Japan Frequency (N=18), n (%) |
Symptom |
||
Fatigue |
22 (95.6) |
16 (88.8) |
Bruising |
18 (78.2) |
7 (38.8) |
Weakness |
18 (78.2) |
15 (65.2) |
Dizziness |
15 (65.2) |
12 (52.1) |
Shortness of Breath |
13 (56.5) |
15 (65.2) |
Bleeding |
12 (52.1) |
13 (72.2) |
Impact |
||
Decreased ability to maintain social/familial roles |
21 (91.3) |
13 (72.2) |
Anxiety |
20 (86.9) |
17 (94.4) |
Decreased ability to function |
20 (86.9) |
17 (94.4) |
Depression |
16 (69.5) |
7 (38.8) |
Fear |
15 (65.2) |
12 (52.1) |
Remission uncertainty |
15 (65.2) |
17 (94.4) |
Appetite loss |
14 (60.8) |
13 (72.2) |
Low sex drive |
11 (47.8) |
7 (38.8) |
Disclosures: Tomaszewski: Astellas Pharma, Inc.: Consultancy . Fickley: Astellas Pharma, Inc.: Consultancy . Maddux: Astellas Pharma, Inc.: Consultancy . Krupnick: Astellas Pharma, Inc.: Consultancy . Bahceci: Astellas Pharma Global Development: Employment . Paty: Astellas Pharma, Inc.: Consultancy . van Nooten: Astellas: Employment .
See more of: Health Services and Outcomes Research – Malignant Diseases
See more of: Oral and Poster Abstracts
*signifies non-member of ASH